Principal Financial Group Inc Y M Abs Therapeutics, Inc. Transaction History

Principal Financial Group Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	BUY	$9.95 - $15.39 $201,925 - $312,324	20,294 New	20,294 $266,000
Q1 2024 Apr 29, 2024	SELL	$6.57 - $18.69 $7,227 - $20,559	-1,100 Reduced 7.42%	13,729 $223,000
Q4 2023 Feb 07, 2024	SELL	$4.88 - $7.42 $1,903 - $2,893	-390 Reduced 2.56%	14,829 $101,000
Q3 2023 Nov 02, 2023	BUY	$4.86 - $7.23 $7,275 - $10,823	1,497 Added 10.91%	15,219 $82,000
Q2 2023 Aug 07, 2023	BUY	$5.68 - $10.34 $15,733 - $28,641	2,770 Added 25.29%	13,722 $93,000
Q1 2023 May 09, 2023	SELL	$2.83 - $5.11 $2,006 - $3,622	-709 Reduced 6.08%	10,952 $54,000
Q4 2022 Feb 09, 2023	BUY	$3.0 - $15.17 $3,810 - $19,265	1,270 Added 12.22%	11,661 $56,000
Q3 2022 Nov 09, 2022	SELL	$13.96 - $19.67 $2,847 - $4,012	-204 Reduced 1.93%	10,391 $150,000
Q2 2022 Aug 10, 2022	BUY	$8.22 - $15.13 $87,090 - $160,302	10,595 New	10,595 $160,000
Q4 2021 Feb 09, 2022	SELL	$15.51 - $29.31 $247,710 - $468,110	-15,971 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$27.47 - $37.31 $163,034 - $221,434	5,935 Added 59.14%	15,971 $455,000
Q2 2021 Aug 10, 2021	BUY	$25.45 - $37.64 $29,216 - $43,210	1,148 Added 12.92%	10,036 $339,000
Q1 2021 May 10, 2021	SELL	$29.16 - $51.96 $207,619 - $369,955	-7,120 Reduced 44.48%	8,888 $269,000
Q4 2020 Feb 08, 2021	BUY	$37.86 - $54.26 $291,673 - $418,019	7,704 Added 92.77%	16,008 $792,000
Q3 2020 Nov 06, 2020	SELL	$35.13 - $43.62 $187,769 - $233,148	-5,345 Reduced 39.16%	8,304 $318,000
Q2 2020 Aug 05, 2020	BUY	$23.66 - $49.53 $322,935 - $676,034	13,649 New	13,649 $590,000

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $356M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.